Travis Steed
Stock Analyst at B of A Securities
(2.66)
# 1,976
Out of 5,241 analysts
102
Total ratings
43.84%
Success rate
5.29%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Neutral | $35 → $25 | $13.56 | +84.37% | 4 | May 18, 2026 | |
| PODD Insulet | Maintains: Buy | $288 → $208 | $153.15 | +35.81% | 4 | May 18, 2026 | |
| MMED MiniMed Group | Maintains: Buy | $27 → $20 | $11.08 | +80.51% | 2 | May 18, 2026 | |
| ISRG Intuitive Surgical | Maintains: Buy | $650 → $520 | $437.22 | +18.93% | 3 | May 18, 2026 | |
| EMBC Embecta | Maintains: Underperform | $11 → $3 | $3.02 | -0.66% | 2 | May 18, 2026 | |
| CNMD CONMED | Maintains: Neutral | $52 → $40 | $36.24 | +10.38% | 6 | May 18, 2026 | |
| BBNX Beta Bionics | Maintains: Neutral | $23 → $11 | $9.19 | +19.70% | 2 | May 18, 2026 | |
| DXCM DexCom | Maintains: Buy | $100 → $80 | $64.18 | +24.65% | 8 | May 18, 2026 | |
| ABT Abbott Laboratories | Maintains: Buy | $150 → $120 | $87.12 | +37.74% | 6 | Apr 17, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $325.70 | +13.60% | 2 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $207 | $143.11 | +44.64% | 10 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $162 | $178.71 | -9.35% | 1 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $80 → $85 | $75.57 | +12.48% | 3 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $82 → $90 | $81.91 | +9.88% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $16.42 | +94.88% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $45 | $17.74 | +153.66% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $3.68 | +1,122.83% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $312.93 | +0.66% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $41.53 | -61.47% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $85.33 | +87.51% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.29 | +522.57% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.05 | +504.98% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $76.79 | +88.83% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $55.52 | -8.14% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $14.29 | +277.89% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $93.36 | -76.44% | 1 | Jul 17, 2017 |
Tandem Diabetes Care
May 18, 2026
Maintains: Neutral
Price Target: $35 → $25
Current: $13.56
Upside: +84.37%
Insulet
May 18, 2026
Maintains: Buy
Price Target: $288 → $208
Current: $153.15
Upside: +35.81%
MiniMed Group
May 18, 2026
Maintains: Buy
Price Target: $27 → $20
Current: $11.08
Upside: +80.51%
Intuitive Surgical
May 18, 2026
Maintains: Buy
Price Target: $650 → $520
Current: $437.22
Upside: +18.93%
Embecta
May 18, 2026
Maintains: Underperform
Price Target: $11 → $3
Current: $3.02
Upside: -0.66%
CONMED
May 18, 2026
Maintains: Neutral
Price Target: $52 → $40
Current: $36.24
Upside: +10.38%
Beta Bionics
May 18, 2026
Maintains: Neutral
Price Target: $23 → $11
Current: $9.19
Upside: +19.70%
DexCom
May 18, 2026
Maintains: Buy
Price Target: $100 → $80
Current: $64.18
Upside: +24.65%
Abbott Laboratories
Apr 17, 2026
Maintains: Buy
Price Target: $150 → $120
Current: $87.12
Upside: +37.74%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $325.70
Upside: +13.60%
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $143.11
Upside: +44.64%
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $178.71
Upside: -9.35%
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $75.57
Upside: +12.48%
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $81.91
Upside: +9.88%
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $16.42
Upside: +94.88%
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $17.74
Upside: +153.66%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $3.68
Upside: +1,122.83%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $312.93
Upside: +0.66%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $41.53
Upside: -61.47%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $85.33
Upside: +87.51%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.29
Upside: +522.57%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.05
Upside: +504.98%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $76.79
Upside: +88.83%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $55.52
Upside: -8.14%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $14.29
Upside: +277.89%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $93.36
Upside: -76.44%